Calcineurin Inhibitor Versus Sirolimus As Immunosuppressive Partners with Ptcy-Based GVHD Prophylaxis in Adults Undergoing Hematopoietic Cell Transplantation for Hematologic Malignancies: A CIBMTR Analysis | Synapse
March 3, 2026
Calcineurin Inhibitor Versus Sirolimus As Immunosuppressive Partners with Ptcy-Based GVHD Prophylaxis in Adults Undergoing Hematopoietic Cell Transplantation for Hematologic Malignancies: A CIBMTR Analysis
Key Points
Calcineurin inhibitors may be more effective in reducing GVHD risk compared to sirolimus.
The analysis showed that patients receiving calcineurin inhibitors had better outcomes with GVHD rates of 20% versus 30% for sirolimus.
CIBMTR data were examined in this retrospective cohort analysis to assess treatment outcomes.
These findings highlight the need for tailored immunosuppressive strategies in hematologic malignancies.